Explore the vast range of titles available.

In lithium-ion battery management systems (BMSs), accurate state of charge (SOC) estimation is essential for the stable operation of BMSs. Furthermore, the accuracy of SOC estimation is significantly influenced by the precision of battery model parameters. To improve the SOC estimation accuracy, this paper focuses on the second-order RC equivalent circuit model, firstly designs a simple and reliable improved adaptive forgetting factor (IAFF) regulation mechanism, and proposes the improved adaptive forgetting factor recursive least squares (IAFFRLS) algorithm, which not only improves the accuracy of parameter identification, but also exhibits excellent performance in anti-interference. Secondly, based on the identified model, a weighted multi-innovation improved Sage–Husa adaptive extended Kalman filter (WMISAEKF) algorithm is proposed to solve the problem of filter divergence caused by noise covariance updating. It fully utilizes historical innovations to reasonably allocate innovation weights to achieve accurate SOC estimation. Compared with the VFFRLS algorithm and AFFRLS algorithm, the IAFFRLS algorithm reduces the root mean square error (RMSE) by 29.30% and 19.29%, respectively, and the RMSE under noise interference is decreased by 82.37% and 78.59%, respectively. Based on the identified model for SOC estimation, the WMISAEKF algorithm reduces the RMSE by 77.78%, compared to the EKF algorithm. Furthermore, the WMISAEKF algorithm could still converge under different levels of noise interference and incorrect initial SOC values, which proves that the proposed algorithm has good stability and robustness. Simulation results verify that the parameter identification algorithm proposed in this paper demonstrates higher identification accuracy and anti-interference performance. The proposed SOC estimation algorithm has higher estimation accuracy and good robustness, which provides a new practical support for extending battery life.

The antiangiogenic multi-kinase inhibitors (MKIs) apatinib, donafenib, and anlotinib have demonstrated satisfactory efficacy in radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) in their phase II/III trials. However, the potential impact factors on the efficacy of these MKIs remain unclear. RAIR-DTC patients enrolled in clinical trials of apatinib, donafenib, and anlotinib in our center were retrospectively reviewed. The Kaplan-Meier method was used to examine the relationship between clinicopathological variables and progression-free survival (PFS) and overall survival (OS), followed by a multivariate Cox analysis on PFS. A total of 71 progressive RAIR-DTC patients were reviewed, of which 26.7% were treated by anlotinib, 45.1% by apatinib, and 28.2% by donafenib. The median follow-up time was 44.1 months, the median PFS was 21.1 months, and the estimated median OS was 47.7 months. PFS and OS showed no significant differences in patients treated with apatinib, donafenib, or anlotinib. In the univariate analyses, patients with BRAF mutation showed longer PFS (HR 0.345, 95% CI 0.187-0.636, p < 0.001) and OS (HR 0.382, 95% CI 0.166-0.878, p = 0.019) compared with patients with wild-type BRAF. Patients with follicular thyroid cancer and bone metastases had shorter PFS, and patients with worse Eastern Cooperative Oncology Group performance status, bone metastases, and a larger tumor burden had shorter OS. In the multivariate Cox analysis, BRAF mutation was the only independent predictor of longer PFS (HR 0.296, 95% CI 0.138-0.638, p = 0.002). The overall response rate and disease control rate didn't differ between BRAF mutation status. Subgroup analysis of PFS in papillary thyroid cancer patients stratified by BRAF mutation status showed that BRAF mutation was associated with longer PFS in all clinicopathological subgroups (hazard ratio < 1). RAIR-DTC patients with BRAF mutation treated with apatinib, donafenib, or anlotinib achieved better prognoses compared with patients with wild-type BRAF, indicating that the genetic background may play a role in predicting the efficacy of MKIs therapies. This retrospective cohort included patients in our center from clinical trials of apatinib (NCT02731352, NCT03048877), donafenib (NCT02870569, NCT03602495), and anlotinib (NCT05007093).

Medicinal plants have been known as a rich source of natural products (NPs). Due to their diverse chemical structures and remarkable pharmacological activities, NPs are regarded as important repertoires for drug discovery and development. Biebersteinia plant species belong to the Biebersteiniaceae family, and have been used in folk medicines in China and Iran for ages. However, the chemical properties, bioactivities and modes of action of the NPs produced by medicinal Biebersteinia species are poorly understood despite the fact that there are only four known Biebersteinia species worldwide. Here, we reviewed the chemical classifications and diversity of the various NPs found in the four known Biebersteinia species. We found that the major chemical categories in these plants include flavonoids, alkaloids, phenylpropanoids, terpenoids, essential oils and fatty acids. We also discussed the anti-inflammatory, analgesic, antibacterial, antioxidant, antihypertensive and hypoglycemic effects of the four Biebersteinia species. We believe that the present review will facilitate the exploration of traditional uses and pharmacological properties of Biebersteinia species, extraction of the NPs and elucidation of their molecular mechanisms, as well as the development of novel drugs based on the reported properties and mode-of-action.

99mTc-3PRGD2, a promising tracer targeting integrin receptor, may serve as a novel tumor-specific agent for single photon emission computed tomography (SPECT). A multi-center study was prospectively designed to evaluate the diagnostic accuracy of 99mTc-3PRGD2 imaging for bone metastasis in patients with lung cancer in comparison with the conventional 99mTc-MDP bone scan. The patients underwent whole-body scan and chest tomography successively at both 1 h and 4 h after intravenous injection of 11.1 MBq/Kg 99mTc-3PRGD2. 99mTc-MDP whole-body bone scan was routinely performed within 1 week for comparison. Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images. The final diagnosis was established based on the comprehensive assessment of all available data. A total of 44 patients (29 male, 59±10 years old) with suspected lung cancer were recruited from 4 centers. Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign. In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively. The corresponding diagnostic values for 99mTc-MDP bone scan were 87.6%, 60.9%, and 82.1%, respectively in the same patients. 99mTc-MDP bone scan had better contrast in most lesions, whereas the 99mTc-3PRGD2 imaging seemed to be more effective to exclude pseudo-positive lesions and detect bone metastases without osteogenesis. 99mTc-3PRGD2 is a novel tumor-specific agent based on SPECT technology with a promising value in diagnosis of bone metastasis in patients with lung cancer. ClinicalTrials.gov NCT01737112.

Background The antiangiogenic multi-kinase inhibitors (MKIs) apatinib, donafenib, and anlotinib have demonstrated satisfactory efficacy in radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) in their phase II/III trials. However, the potential impact factors on the efficacy of these MKIs remain unclear. Methods RAIR-DTC patients enrolled in clinical trials of apatinib, donafenib, and anlotinib in our center were retrospectively reviewed. The Kaplan–Meier method was used to examine the relationship between clinicopathological variables and progression-free survival (PFS) and overall survival (OS), followed by a multivariate Cox analysis on PFS. Results A total of 71 progressive RAIR-DTC patients were reviewed, of which 26.7% were treated by anlotinib, 45.1% by apatinib, and 28.2% by donafenib. The median follow-up time was 44.1 months, the median PFS was 21.1 months, and the estimated median OS was 47.7 months. PFS and OS showed no significant differences in patients treated with apatinib, donafenib, or anlotinib. In the univariate analyses, patients with BRAF V600E mutation showed longer PFS (HR 0.345, 95% CI 0.187–0.636, p  < 0.001) and OS (HR 0.382, 95% CI 0.166–0.878, p  = 0.019) compared with patients with wild-type BRAF . Patients with follicular thyroid cancer and bone metastases had shorter PFS, and patients with worse Eastern Cooperative Oncology Group performance status, bone metastases, and a larger tumor burden had shorter OS. In the multivariate Cox analysis, BRAF V600E mutation was the only independent predictor of longer PFS (HR 0.296, 95% CI 0.138–0.638, p  = 0.002). The overall response rate and disease control rate didn’t differ between BRAF V600E mutation status. Subgroup analysis of PFS in papillary thyroid cancer patients stratified by BRAF V600E mutation status showed that BRAF V600E mutation was associated with longer PFS in all clinicopathological subgroups (hazard ratio < 1). Conclusion RAIR-DTC patients with BRAF V600E mutation treated with apatinib, donafenib, or anlotinib achieved better prognoses compared with patients with wild-type BRAF , indicating that the genetic background may play a role in predicting the efficacy of MKIs therapies. Trial registration This retrospective cohort included patients in our center from clinical trials of apatinib (NCT02731352, NCT03048877), donafenib (NCT02870569, NCT03602495), and anlotinib (NCT05007093).

In view of rock burst accidents frequently occurring, a basic framework for an intelligent early warning system for rock bursts (IEWSRB) is constructed based on several big data technologies in the computer industry, including data mining, databases and data warehouses. Then, a data warehouse is modeled with regard to monitoring the data of rock bursts, and the effective application of data mining technology in this system is discussed in detail. Furthermore, we focus on the K-means clustering algorithm, and a data visualization interface based on the Browser/Server (B/S) mode is developed, which is mainly based on the Java language, supplemented by Cascading Style Sheets (CSS), JavaScript and HyperText Markup Language (HTML), with Tomcat, as the server and Mysql as the JavaWeb project of the rock burst monitoring data warehouse. The application of data mining technology in IEWSRB can improve the existing rock burst monitoring system and enhance the prediction. It can also realize real-time queries and the analysis of monitoring data through browsers, which is very convenient. Hence, it can make important contributions to the safe and efficient production of coal mines and the sustainable development of the coal economy.

.sup.99m Tc-3PRGD2, a promising tracer targeting integrin receptor, may serve as a novel tumor-specific agent for single photon emission computed tomography (SPECT). A multi-center study was prospectively designed to evaluate the diagnostic accuracy of .sup.99m Tc-3PRGD2 imaging for bone metastasis in patients with lung cancer in comparison with the conventional .sup.99m Tc-MDP bone scan. The patients underwent whole-body scan and chest tomography successively at both 1 h and 4 h after intravenous injection of 11.1 MBq/Kg .sup.99m Tc-3PRGD2. .sup.99m Tc-MDP whole-body bone scan was routinely performed within 1 week for comparison. Three experienced nuclear medicine physicians blindly read the .sup.99m Tc-3PRGD2 and .sup.99m Tc-MDP images. The final diagnosis was established based on the comprehensive assessment of all available data. A total of 44 patients (29 male, 59±10 years old) with suspected lung cancer were recruited from 4 centers. Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign. In a lesion-based analysis, .sup.99m Tc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively. The corresponding diagnostic values for .sup.99m Tc-MDP bone scan were 87.6%, 60.9%, and 82.1%, respectively in the same patients. .sup.99m Tc-MDP bone scan had better contrast in most lesions, whereas the .sup.99m Tc-3PRGD2 imaging seemed to be more effective to exclude pseudo-positive lesions and detect bone metastases without osteogenesis. .sup.99m Tc-3PRGD2 is a novel tumor-specific agent based on SPECT technology with a promising value in diagnosis of bone metastasis in patients with lung cancer.

Integrin α(v)β(3) has been proposed as a potential imaging target for radiolabeled RGD peptides and a molecular marker for the estimation of tumor angiogenesis, yet it has not been applied in differentiated thyroid cancer (DTC) patients with radioactive iodine-refractory (RAIR) lesions. The current study was conducted to assess the potential of integrin α(v)β(3) imaging in the detection of RAIR DTC lesions using (99m)Tc-PEG(4)-E[PEG(4)-c(RGDfK)](2) ((99m)Tc-3PRGD2), thus providing a feasible antiangiogenetic therapeutic target. Ten DTC patients (2 men, 8 women; mean age ± SD, 56.4 ± 9.8 y; age range, 42-73 y) with multiple RAIR metastases were recruited; all patients had both elevated thyroglobulin levels (thyroglobulin-positive) and negative (131)I whole-body scan (WBS) results. Clinical data were collected including history, (131)I WBS, contemporary CT, ultrasonography, thyroid-stimulating hormone, thyroglobulin, and antithyroglobulin. One or 2 target lesions were selected on the contemporary CT images using Response Evaluation Criteria in Solid Tumors 1.0 for all patients, 7 of whom were chosen for the calculation of the rates of lesion growth within the 3 mo before the study. WBS at 30 min and regional SPECT for lesions at 1 h were performed after the intravenous injection of (99m)Tc-3PRGD2. Two experienced nuclear medicine physicians read the images in a masked fashion. The tumor-to-background ratios were calculated for further analysis. All the target RAIR metastatic lesions were identified as positive on (99m)Tc-3PRGD2 SPECT images. There was a significant correlation between the mean tumor-to-background ratios and mean growth rates of target lesions (r = 0.878, P = 0.009). The RAIR ((131)I WBS-negative/thyroglobulin-positive) metastatic lesions can be traced using (99m)Tc-3PRGD2 imaging, meaning these lesions are highly neovascularized. (99m)Tc-3PRGD2 angiogenesis imaging can be used for the localization and growth evaluation of RAIR lesions, providing a new therapeutic target and a novel imaging modality to monitor the efficacy of certain antiangiogenetic therapy.